GVOKE KIT
Peakglucagon injection, solution
NDASUBCUTANEOUSSOLUTION
Approved
Sep 2019
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
4/8 — Partial
GVOKE KIT (glucagon injection, solution) is 12. First approved in 2019.
Drug data last refreshed 4d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
GVOKE KIT is a ready-to-use glucagon injection solution administered subcutaneously for emergency treatment of severe hypoglycemia in patients with diabetes. It works by activating hepatic glucagon receptors to stimulate glycogen breakdown and glucose release from the liver. The product is designed for rapid response in acute hypoglycemic episodes, with documented efficacy across adult and pediatric populations with type 1 diabetes.
Peak10.0 years to LOE
Product is in peak commercial phase with stable market position; brand team likely at full operational capacity with focus on market penetration and patient access.
Mechanism of Action
12.1 Mechanism of Action Glucagon increases blood glucose concentration by activating hepatic glucagon receptors, thereby stimulating glycogen breakdown and release of glucose from the liver. Hepatic stores of glycogen are necessary for glucagon to produce an antihypoglycemic effect. Extrahepatic…
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.